journal article·2017-11

Thermosensitive Hydrogel Containing Doxycycline Exerts Inhibitory Effects on Abdominal Aortic Aneurysm Induced By Pancreatic Elastase in Mice

Maomao Yu, Anjie Dong, Cong Chen, Shuxin Xu, Yini Cao, Shu Liu, Qiang Zhang, Rong Qi

Advanced Healthcare Materials· Volume 6· Issue 22
Publisher page

Abstract

Abstract Doxycycline (DOX) is reported to exert therapeutic effects against abdominal aortic aneurysm (AAA), a severe degenerative disease. In this study, a DOX hydrogel formulation of DOX/PECTgel is studied, and its phase transition behavior and in vitro release profiles are explored. In addition, the anti‐AAA effects and bioavailability of DOX/PECTgel are evaluated in an elastase induced AAA mouse model. The results show that the phase transition temperature of 30% poly(e‐caprolactone‐co‐1,4,8‐trioxa[4.6]spiro‐9‐undecanone) (PECT) solution is above 34 °C. In vitro release profiles of DOX/PECTgel indicate a fast release of DOX at the first two days, followed by a slow and sustained release for 14 d. In vivo single‐dose single subcutaneous injection of DOX/PECTgel containing 8.4 or 4.2 mg mL−1 DOX presents comparatively preventive effects on AAA, compared to intraperitoneal injections of DOX alone at a dose of 15 mg kg−1 for seven injections, while DOX bioavailability of the DOX/PECTgel treated groups is 1.39 times or 1.19 times of the DOX alone treated group, respectively.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Aortic aneurysm repair treatments · Cardiac and Coronary Surgery Techniques · Abdominal vascular conditions and treatments

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Peking University Institute of Cardiovascular Sciences Key Laboratory of Molecular Cardiovascular Sciences Ministry of Education Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems Peking University Health Science Center 38 Xueyuan Road Beijing 100191 China

School of Chemical Engineering and Technology Tianjin University Tianjin 300072 China

Shihezi University College of Pharmacy/Key Laboratory of Xinjiang Endemic Phytomedicine Resources Ministry of Education Xinjiang 832003 China

Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems School of Pharmaceutical Sciences Peking University 38 Xueyuan Road Beijing 100191 China

Funding

National Natural Science Foundation of China

References (36)

Show source-provided references
1. 10.1136/heartjnl-2014-30564810.1136/heartjnl-2014-305648 ↗
2. 10.1016/S0741-5214(99)70018-210.1016/S0741-5214(99)70018-2 ↗
3. Rughani G. · Cochrane Database Syst. Rev. · 2012 · 9 · CD009536
4. 10.1161/CIRCULATIONAHA.107.73527410.1161/CIRCULATIONAHA.107.735274 ↗
5. 10.1067/mva.2002.12157210.1067/mva.2002.121572 ↗
6. 10.1016/j.ejvs.2005.10.00710.1016/j.ejvs.2005.10.007 ↗
7. 10.1016/j.jvs.2008.07.01410.1016/j.jvs.2008.07.014 ↗
8. 10.1016/j.pcad.2007.05.00110.1016/j.pcad.2007.05.001 ↗
9. 10.1016/j.jvs.2014.04.06710.1016/j.jvs.2014.04.067 ↗
10. 10.1067/mva.2001.11696610.1067/mva.2001.116966 ↗
11. 10.1016/j.jtcvs.2009.07.07510.1016/j.jtcvs.2009.07.075 ↗
12. 10.1016/S1078-5884(98)80034-810.1016/S1078-5884(98)80034-8 ↗
13. 10.1371/journal.pone.003969510.1371/journal.pone.0039695 ↗
14. 10.1111/j.1600-0765.1985.tb00405.x10.1111/j.1600-0765.1985.tb00405.x ↗
15. 10.2174/15701611179619728810.2174/157016111796197288 ↗
16. 10.1111/j.1540-9740.2003.03014.x10.1111/j.1540-9740.2003.03014.x ↗
17. Pfeffer I. · J. Dtsch. Dermatol. Ges. · 2011 · 9 · 904
18. 10.1517/17425247.2011.58165610.1517/17425247.2011.581656 ↗
19. 10.2174/092986731130201000910.2174/0929867311302010009 ↗
20. 10.1039/C1CS15203C10.1039/C1CS15203C ↗
21. 10.1016/j.jconrel.2006.11.02410.1016/j.jconrel.2006.11.024 ↗
22. 10.1016/j.biomaterials.2011.11.07810.1016/j.biomaterials.2011.11.078 ↗
23. 10.1016/j.biomaterials.2011.03.03110.1016/j.biomaterials.2011.03.031 ↗
24. 10.1016/S0168-3659(01)00276-010.1016/S0168-3659(01)00276-0 ↗
25. 10.1016/S0168-3659(99)00194-710.1016/S0168-3659(99)00194-7 ↗
26. 10.1016/j.jconrel.2011.12.00110.1016/j.jconrel.2011.12.001 ↗
27. 10.1016/j.carbpol.2014.03.01610.1016/j.carbpol.2014.03.016 ↗
28. 10.1016/j.actbio.2012.07.02110.1016/j.actbio.2012.07.021 ↗
29. 10.1016/j.surg.2012.02.01010.1016/j.surg.2012.02.010 ↗
30. 10.1016/j.ejpb.2012.04.00810.1016/j.ejpb.2012.04.008 ↗
31. 10.1016/j.addr.2006.09.00410.1016/j.addr.2006.09.004 ↗
32. 10.1016/j.ejps.2014.06.00210.1016/j.ejps.2014.06.002 ↗
33. 10.1039/c2bm00159d10.1039/c2bm00159d ↗
34. Pendri A. · Anticancer Drug Des. · 1998 · 13 · 387
35. 10.1021/ar00023a00110.1021/ar00023a001 ↗
36. 10.1016/j.ejvs.2012.11.01510.1016/j.ejvs.2012.11.015 ↗